Non-Hodgkin's lymphoma: Role of high-dose therapy in diffuse large B-cell lymphoma by Cerny, Thomas & Betticher, Daniel
Role of high-dose therapy in diffuse large B-cell lymphoma
Thomas Cernya and Daniel Betticher b
' Department Internal Medicine, Head of Oncology / Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
b
 Institute of Medical Oncology, University of Berne, Inselspital, Berne, Switzerland
Introduction
Diffuse large B-cell lymphoma is the most frequent
Non Hodgkin's Lymphoma entity seen in the west-
era world, over 30% of all cases. Furthermore, the
disease incidence is increasing in most western coun-
tries. Although it is a curable disease most patients
will eventually die due to disease accounting for
relapse. Despite many attempts during the last three
decades to increase the cure rate of 35 to 40%,
we have not yet succeeded in improving the results
significantly since CHOP (cyclophosphamide, dox-
orubicin, vincristine, prednisone) chemotherapy was
introduced in the 1970s [1]. Second and third gen-
eration regimens as compared to the first generation
CHOP failed to demonstrate an advantage over the
CHOP regimen [2,3]. More recently, attempts to im-
prove treatment outcome have focused on increasing
the dose intensity of cytotoxic drugs by applying
high-dose chemotherapy, with or without involved
field or total body irradiation, supported by autolo-
gous haematopoietic stem cell transplantation. Autol-
ogous bone marrow and, more recently, autologous
haematopoietic stem cells collected from peripheral
blood after mobilisation from bone marrow have
both been used to assure haematopoietic reconsti-
tution after high-dose myeloablative chemotherapy.
The availability of haematopoietic growth factors has
facilitated both the mobilisation of haematopoietic
stem cells into the peripheral blood and the appli-
cation of high-dose chemotherapy programs [4-8].
Furthermore efficient purging procedures of stem
cells before reinfusion is an other important step
towards improving treatment results.
Important clinical and biological prognostic fac-
tors as well as molecular therapeutic targets have
been identified and are instrumental in further im-
proving our treatment strategy.
High-dose chemotherapy with autologous stem
cell support in relapsed patients
The well-known Parma trial examined the value of
autologous bone-marrow transplantation compared
with salvage chemotherapy in relapses of chemother-
apy-sensitive non-Hodgkin's lymphoma [9]. Patients
having relapsed after an initial complete remission
and younger than 60 years with no evidence of CNS
or bone marrow involvement were first treated with
two courses of conventional salvage chemotherapy.
Patients responding with at least a partial response
(PR) were then considered to be chemosensitive and
randomised to involved field radiotherapy and high-
dose BEAC (carmustine, etoposide, cytarabine, cy-
clophosphamide) chemotherapy versus DHAP (dex-
amethasone, high-dose Ara-C, cisplatin) chemother-
apy for six additional months followed by involved
field radiotherapy. The event-free survival was 46%
for the high-dose arm compared to 12% patients with
conventional salvage chemotherapy. There was also
an advantage in overall survival for the high-dose
therapy group. The conclusion was that high-dose
therapy with stem-cell, support is the treatment of
choice for relapsed aggressive lymphoma patients
using the criteria of the Parma study. These results
have been confirmed in other trials and with other
treatment regimens [10-15].
The European bone marrow transplant group
(EBMT) has collected the data of patients treated
in first or later relapse [16]. The most important
prognostic factor seems to be sensitivity to chem-
otherapy. There is a group of patients who are in
long-term remission but we do not have a detailed
understanding of which factors other than sensitiv-
ity to salvage therapy and bulk of disease are the
most important in predicting beneficial or deleterious
outcome.
Although patients with a chemosensitive relapse
have a chance of cure no such results are obtained
in patients with truly chemoresistant disease or early
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relapse within 3 months of completion of chemo-
therapy. If ever these unfortunate patients are well
enough they are candidates for experimental innova-
tive treatment options.
The International Prognostic Index (EPI)
The international non-Hodgkin's lymphoma prognos-
tic factors project derived a model of pre-treatment
factors for outcome among patients treated with dox-
orubicin-based chemotherapy regimens [17]. Five
criteria at initial presentation were found to be in-
dependent and significant poor risk factors, i.e. age
>60 years, advanced stage, increased LDH, >1 ex-
tranodal site of disease, and poor performance status.
These five features were used to design a model to
predict an individual patient's risk of death — the
International Prognostic Index.
With the introduction of the International Prog-
nostic Index (IPI) we now have:
(1) a valid measure for comparison and understand-
ing of different outcomes of treatment studies in
patients with aggressive NHL and
(2) the possibility of a primary risk-adapted choice
of initial therapy for individual patients.
Since the age limit for treatment with intensive
regimens is generally set at 60 years, an age-adjusted
International Index was also created for younger
(<60 years) patients. Three of the previously iden-
tified risk factors — stage, performance status, and
LDH level — proved to be independent signif-
icant adverse prognostic factors for this younger
age group. With conventional combination chemo-
therapy, patients <60 years old will have a 5-year
survival rate of approximately 46% if 2 of these
risk factors are present, and a 5-year survival rate of
approximately 32% if all 3 risk factors are present.
The IPI should now be further developed by
including new biological markers of prognostic im-
portance.
First-line high-dose chemotherapy in relation to
the DPI
Several investigators have included high-dose chem-
otherapy programs as an integral part of the initial
management of high-risk NHL patients, but risk fac-
tors were not generally assessed according to the
IPI. Results of a prospective randomised trial have
been reported in which the value of early high-dose
chemoradiotherapy with autologous bone marrow
transplantation was evaluated in patients with ag-
gressive NHL who had slow responses to first line
CHOP therapy (i.e., incomplete remissions after 3
cycles). In this trial, the outcome was not improved
by high-dose treatment as compared to conventional
therapy [18]. In another prospective randomised trial,
high-dose chemotherapy with autologous bone mar-
row transplantation was compared to conventional
chemotherapy as consolidation treatment in high-risk
patients with intermediate grade or high grade NHL
in first complete remission. High-dose consolidation
failed to improve relapse free survival time and over-
all survival time in these patients [19]. In view of
the negative results obtained in these randomised
prospective studies, it is difficult to interpret the
results of other non-randomised trials although out-
come in some of them is favourable compared with
historical controls [20-25].
Following the description of the IPI, the results of
the LNH-87 trial were re-analysed according to IPI
risk groups [26]. Patients in the high/intermediate
(H/I) and high (H) risk groups had superior DFS
and overall survival (OS) rates when treated with
high-dose consolidation and autologous stem cell
transplantation (ASCT) compared with those patients
who received conventional dose sequential consoli-
dation therapy (5 year actuarial DFS = 57% for high
dose versus 36% for conventional dose [p = 0.01]; 5
year actuarial OS = 65% for high dose versus 52%
for conventional dose [p = 0.06]). No difference in
OS or DFS was observed for patients in the low (L)
or low/intermediate (L/I) risk groups. These data
must be interpreted cautiously, since they represent
a retrospective, subset analysis from a non-stratified
prospective clinical trial, but they suggest a possi-
ble role for high dose consolidation in patients with
poor-risk disease.
Several randomised trials of early intensification,
using high dose therapy and ASCT have now been
reported for poor risk patients, and several others are
in progress:
• GELA have recently reported results for the
LNH-93 trial [27]. This was a randomised
comparison of conventional chemotherapy us-
ing ACVB (doxorubicin, cyclophosphamide, vin-
blastine, bleomycin) followed by conventional
dose sequential consolidation therapy, compared
with an experimental intensified induction regi-
men (CEOP [cyclophosphamide, epirubicin, vin-
cristine, prednisone] plus ECVBP [epirubicin,
cyclophosphamide, vindesine, bleomycin, pred-
nisone]) followed by high dose therapy and ASCT.
Patients aged < 60 years, with 2 or 3 adverse risk
factors according to the age-adjusted IPI were
eligible. Accrual to the trial was closed after an
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interim analysis. At the time of the most recent
report, with a median follow up of 30 months, the
3 year EFS was 54% for the conventional arm ver-
sus 41% for the high dose arm (p = 0.01), and the
3 year OS was 63% for the conventional dose arm
versus 47% for the high dose arm (p = 0.003).
• The German High Grade Lymphoma Study Group
are conducting a trial comparing 3 cycles of
chemotherapy using CHEOP (cyclophosphamide,
doxorubicin, etoposide, vincristine, prednisone)
followed by high dose therapy and ASCT, with 5
cycles of CHEOP alone, for patients aged < 60,
with an elevated LDH [28]. No difference in DFS
or OS was reported at the first interim analysis of
this trial, and a subsequent analysis using IPI risk
groups shows no differences in outcome to date.
• The Italian NHL Study Group have recently com-
pleted a trial comparing VACOP-B (etoposide,
doxorubicin, cyclophosphamide, vincristine, pred-
nisone) alone with VACOP-B followed by high
dose therapy and ASCT for poor risk patients
(defined as bulky stage n, stages HI and IV) [29].
When all patients were analysed, no difference in
DFS or OS was observed. Subset analysis showed
a significant improvement in DFS for IPI H/I
and H risk groups receiving high dose therapy (6
year actuarial DFS = 87% for high dose com-
pared with 48% for conventional dose therapy,
p = 0.008). However, no difference in progres-
sion-free survival (PFS) or OS was observed.
Recent studies of early intensification have been
notable for the relatively high rate of early disease
progression in patients receiving induction therapy
prior to high dose consolidation. In the Groupe
d'Etudes des Lymphomes de l'Adulte (GELA)
LNH-93-3 trial, 29% of patients had progressed
before reaching the high dose phase of the trial [27].
Similarly, in the German High Grade Lymphoma
Study Group trial, 33% of patients failed to reach the
high dose phase, mainly due to disease progression
[28]. In the current UK Lymphoma Group LY02 trial,
the corresponding figure is approximately 30%. Dou-
ble autotransplant attempts in patients with a poor IPI
have not been successful and the GELA has recently
decided to stop such a pilot study after treating 39
patients.
Sequential high-dose chemotherapy
To potentially improve the efficacy of high-dose
chemotherapy in the initial management of patients
with aggressive NHL, Gianni and colleagues from
Milan developed the concept of sequential high-
dose chemotherapy. This approach is based upon
the sequential administration of non-cross resistant
cytotoxic drugs at near maximally tolerated doses
with colony stimulating factor support in order to
achieve maximal tumour kill with minimal develop-
ment of drug resistance [30]. Several regimens were
evaluated for feasibility, efficacy and toxicity, and a
regimen consisting of five sequentially administered
chemotherapy treatment phases turned out to be most
suitable for clinical usage: an initial cytoreduction
is the goal of phase I; high-dose cyclophosphamide
is used in phase II to mobilise peripheral blood
stem cells while simultaneously providing a highly
active treatment for the malignant disease; high-
dose methotrexate and etoposide are given during
phase HI and IV, respectively; and phase V is a
myeloablative treatment containing melphalan and
mitoxantrone. Eventually, an additional radiotherapy
(phase VI) is given to patients who presented with
bulky disease at diagnosis. This treatment was well
tolerated, with relevant toxicities including grade
HI and IV myelosuppression and mucositis. Toxic
deaths were encountered initially when total body
irradiation (TBI) was given as part of the condi-
tioning therapy, but fatal events could be eliminated
when TBI was replaced by the myeloablative ther-
apy described. A randomised phase HI trial was
then performed in which sequential high-dose treat-
ment was compared to a control arm consisting of a
third generation chemotherapy regimen (MACOP-B:
methotrexate, doxorubicin, cyclophosphamide, vin-
cristine, prednisone and bleomycin) in newly diag-
nosed patients with diffuse large cell NHL and poor
risk factors [31]. After a median follow-up of 43
months, treatment results were better after sequential
high-dose therapy compared with MACOP-B, with
a complete remission rate of 94% vs. 61%, freedom
from progression in 88% vs. 41% of patients, failure-
free survival in 73% vs. 40%, and overall survival in
73% vs. 62% [32].
Several groups in Europe and the US were able
to confirm these results and were able to document
that the sequential high-dose regimen is feasible and
has an acceptable toxicity in lymphoma patients with
poor prognostic features.
The results of the studies outlined above allow the
following preliminary conclusions to be drawn:
1. The use of high dose therapy and ASCT in
first remission (complete or partial) does not improve
DFS or OS for the entire population of patients with
advanced aggressive NHL.
2. Subset analysis of 2 non-stratified trials has
shown a DFS and OS advantage for the high dose
arm, which is restricted to patients with H/I and
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H risk disease. No benefit has been observed for
patients with L/I or L risk disease.
3. The use of early intensification, using high dose
therapy and ASCT prior to the completion of full
induction therapy may be inadequate, based on the
results of the LNH-93-3 trial.
4. The Milan HDS protocol is the only regimen to
date which has produced superior event-free survival
(EFS) compared with standard dose therapy in poor
risk patients in a prospective randomised trial.
The ECOG trial has demonstrated that this chem-
otherapy can be safely delivered in a multi-institu-
tional trial.
Those studies in which sub-set analysis has demon-
strated an advantage for high dose therapy have in-
cluded the high dose regimen at the completion of full
induction chemotherapy.
The encouraging data reported for the use of high-
dose sequential (HDS) therapy require further com-
parison with standard therapy in a multi-centre con-
text in a randomised prospective trial, compared with
standard chemotherapy in patients with IPI high and
high/intermediate risk disease.
The Swiss Group for Clinical Cancer Research
(SAKK) therefore decided to start a multicentre inter-
national randomised phase m trial (MISTRAL) com-
paring the sequential high-dose strategy to standard
CHOP chemotherapy. The study design is shown in
Fig. 1.
I SaquMU Mglvoa* n*n«il
Fig. 1. MISTRAL study design (from the SAKK protocol —
Swiss Group for Clinical Cancer Research — published with
authorization).
Conclusion
High-dose chemotherapy is a potentially curative
treatment option in chemosensitive relapsed patients
with diffuse large B-cell NHL [33]. Its role in the
first line treatment setting is still experimental and
has to be studied in randomised trials such as the
European MISTRAL study or the joint study of
the Southwest Oncology Group (SWOG), Eastern
Cooperative Oncology Group (ECOG) and Cancer
and Leukemia Group B (CALGB) in North America.
We still do not know whether there is a best high dose
regimen and whether there is a role for radiotherapy
or purging of stem cells. The biology of diffuse large
B-cell NHL must be elucidated further in order to
understand the diversity of this heterogenous disease.
New innovative treatment modalities are urgently
needed to rescue patients with primary and secondary
chemotherapy-resistant disease.
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